Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$0.65 - $1.31 $41,679 - $83,999
64,122 New
64,122 $61,000
Q4 2022

Feb 14, 2023

SELL
$0.32 - $0.52 $35,771 - $58,129
-111,787 Reduced 89.88%
12,582 $4,000
Q3 2022

Nov 14, 2022

SELL
$0.43 - $1.56 $12,998 - $47,155
-30,228 Reduced 19.55%
124,369 $53,000
Q2 2022

Aug 15, 2022

BUY
$0.7 - $1.4 $108,217 - $216,435
154,597 New
154,597 $121,000
Q1 2022

May 09, 2022

SELL
$0.63 - $1.59 $27,803 - $70,169
-44,132 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$1.27 - $2.42 $56,047 - $106,799
44,132 New
44,132 $56,000
Q3 2021

Nov 12, 2021

SELL
$2.15 - $3.82 $180,939 - $321,483
-84,158 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$2.89 - $4.45 $243,216 - $374,503
84,158 New
84,158 $316,000
Q1 2021

May 14, 2021

SELL
$2.9 - $4.09 $44,660 - $62,986
-15,400 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$3.38 - $5.14 $127,162 - $193,377
-37,622 Reduced 70.96%
15,400 $53,000
Q3 2020

Nov 12, 2020

BUY
$2.99 - $4.9 $158,535 - $259,807
53,022 New
53,022 $216,000

Others Institutions Holding SPPI

# of Institutions
1
Shares Held
115K
Call Options Held
0
Put Options Held
0

About SPECTRUM PHARMACEUTICALS INC


  • Ticker SPPI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,164,000
  • Description
  • Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...
More about SPPI
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.